PDT Partners LLC Takes $3.37 Million Position in Medpace Holdings, Inc. $MEDP

PDT Partners LLC acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 6,355 shares of the company’s stock, valued at approximately $3,366,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Johnson Financial Group Inc. purchased a new position in shares of Medpace during the second quarter valued at approximately $27,000. Geneos Wealth Management Inc. grew its position in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the last quarter. Elyxium Wealth LLC purchased a new stake in Medpace in the fourth quarter worth $30,000. Jones Financial Companies Lllp purchased a new stake in Medpace in the second quarter worth $30,000. Finally, Allied Private Wealth LLC bought a new stake in shares of Medpace during the second quarter worth $31,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Robert W. Baird upped their price target on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a report on Friday, July 24th. Barclays set a $600.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Truist Financial boosted their price objective on shares of Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Leerink Partners set a $620.00 target price on shares of Medpace in a research report on Thursday, July 23rd. Finally, Weiss Ratings raised shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. Three research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat.com, Medpace currently has a consensus rating of “Hold” and a consensus target price of $584.18.

Medpace Trading Up 0.8%

Shares of NASDAQ MEDP opened at $619.05 on Thursday. Medpace Holdings, Inc. has a 12-month low of $373.00 and a 12-month high of $677.90. The stock’s fifty day simple moving average is $559.49 and its two-hundred day simple moving average is $493.31. The stock has a market capitalization of $17.28 billion, a PE ratio of 36.29, a price-to-earnings-growth ratio of 2.74 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Medpace News Summary

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace remains near a potential technical buy point of $628.92 after its July advance. The stock is trading well above its 50-day and 200-day moving averages, indicating sustained momentum. Medpace Stock Hovers Near Entry, Offers Second Chance After July Spike
• Positive Sentiment: The company’s latest quarterly results exceeded expectations: adjusted earnings were $4.25 per share versus the $3.98 consensus estimate, while revenue rose 17.2% year over year to $707.33 million, surpassing forecasts. Fiscal 2026 EPS guidance remains $17.25 to $17.95.
• Positive Sentiment: Institutional investors and hedge funds own approximately 78% of Medpace, and several investment firms have recently increased their positions. Some analysts have also raised price targets, including RBC’s $692 target and Mizuho’s $665 target.
• Neutral Sentiment: Value-focused investors are comparing Medpace with Concentra Group, but the available report does not establish a clear valuation advantage for MEDP. The stock trades at roughly 36 times earnings, with a PEG ratio above 2.7, suggesting investors are already paying a premium for growth. CON vs. MEDP: Which Stock Should Value Investors Buy Now?
• Neutral Sentiment: Reported short interest was zero shares, producing a zero-day days-to-cover ratio. This provides no meaningful evidence of short-covering demand or downside pressure.
• Negative Sentiment: Several executives have recently sold shares near $620–$625. CEO August Troendle sold 15,978 shares in two transactions worth approximately $9.97 million, while CFO Kevin Brady sold 3,400 shares valued at about $2.13 million. Although both executives retain shares, the concentration of insider selling could weigh on sentiment. Medpace CEO August Troendle Sells 1,983 Shares
• Negative Sentiment: Analyst opinion remains cautious overall: the consensus rating is “Hold,” and the average price target of $584.18 is below recent trading levels. This may make additional upside more difficult without another earnings or guidance catalyst.

Insider Activity at Medpace

In other Medpace news, CEO August J. Troendle sold 1,983 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $620.23, for a total value of $1,229,916.09. Following the completion of the sale, the chief executive officer directly owned 545,217 shares in the company, valued at $338,159,939.91. This trade represents a 0.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Cornelius P. Mccarthy III sold 1,140 shares of Medpace stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $605.37, for a total transaction of $690,121.80. Following the completion of the transaction, the director directly owned 12,275 shares in the company, valued at $7,430,916.75. This represents a 8.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 125,290 shares of company stock valued at $76,466,988 over the last three months. Company insiders own 20.50% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.